NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW.
SCIENION AG today announced that the planned acquisition by Canadian SQI Diagnostics Inc. will not be realized. The share purchase agreement was terminated.
Dortmund and Berlin, October 6, 2011: Dr. Holger Eickhoff, CEO of Scienion AG, stated: “Due to the current situation at the capital markets SQI was not able to raise the capital necessary for the acquisition of Scienion. However, we are still convinced that the technologies of Scienion and SQI fit together very well. Scienion and SQI are currently evaluating a variety of partnering structures allowing the two companies to develop sales opportunities of mutual interest that combine their complementary technologies to solve customer needs for turn-key microarray assays and automated platform solutions.
The planned deal was an interesting option but now we will keep our autonomy as an independent company and continue in doing our successful and profitable business. The company is well-positioned and Scienion‘s products, services and expertise are much in demand. This year’s business is ahead of schedule and we are preparing for major expansion particularly in our key markets.”

About Scienion
Scienion AG provides systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, Scienion offers a unique technology portfolio that has been consequently expanded over one decade. Scienion provides flexible solutions for research and development whereas solutions for production purposes are rather customized. Systems and software are characterized by its versatility, precision and robustness. The company is a renowned specialist for ultra low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. Scienion’s dispensers allow for contact-free and precise drop spotting in the pico- to nano-liter range and are optimally suited for microarray based analytics – as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various carriers.
The company operates from two sites, Dortmund and Berlin.

Contact
SCIENION AG
Holger Eickhoff, CEO
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone +49 (0)30 – 6392 1700
Fax: +49 (0)30 – 6392 1701
[email protected] www.scienion.com Media
SCIENION AG
Almut Gebhard
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone +49 (0)30 – 6392 1700
Fax: +49 (0)30 – 6392 1701
[email protected]
www.scienion.com